Edwin M. Posadas, MD
5.0
25 Reviews
310-423-7600
Fax: 310-967-3841
5.0
25 Reviews
Edwin M. Posadas, MD
Scheduling
In person visits
Fax: 310-967-3841
Samuel Oschin Cancer Center
127 S San Vicente Blvd - 7th Floor
Los Angeles, CA
34.074713 -118.379418From You
5.0
25 Reviews
Edwin M. Posadas, MD
Languages
- English,
- Filipino,
- French,
- Italian,
- Thai,
Gender
Male
Experience
24 Years
Locations
Samuel Oschin Cancer Center
Samuel Oschin Cancer Center
310-423-8030
-
Self-parking is available in Cedars-Sinai parking lot P4. The cost is: 1st hour free, $5 each hour thereafter and $15 daily maximum. Valet parking is the same price as self-parking. Gratuities are not accepted. Valet is available at lot P4 Pavilion M-F, 5 a.m.-10 p.m.
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
1
- IM Hematology Oncology
Programs
Cedars-Sinai clinical programs this provider is part of:
3
Research Areas
Titles
- Co-Director, Experimental Therapeutics Program
- Associate Professor, Medicine
- Medical Director, Urologic Oncology Program
Education & Training
-
National Cancer Institute
Fellowship - Completed 2005
-
University of Michigan Medical School
Residency - Completed 2001
-
Johns Hopkins School of Medicine
Medical School - Completed 1998
Achievements
-
1
Board Certifications
-
10
Awards and Honors
-
6
Publications
Board Certifications
-
IM/Oncology
American Board of Internal Medicine
Awards and Honors
- Sovereign Military Hospitaller Order of Saint John of Jerusalem of Rhodes and of Malta
- American Urologic Association
- Society of Basic Urologic Research
- AACR/NOCC Scholar-in-Training Award
- Biomedical Engineering Award
- Member, Blood Profiling Atlas in Cancer (BloodPAC). White House Cancer Moonshot Program
- Fellow, American College of Physicians
- Catholic Medical Association
- American Association for Cancer Research
- Tau Beta Pi National Engineering Honors Society
Publications
- Posadas EM, Figlin RA. Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park). 2012;26(3):290-301.
- Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, et al. miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Clin Cancer Res. 2014;20(24):6559-6569.
- Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, et al. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene. 2015;34(21):2690-2699.
- Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, et al. miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res. 2014;20(17):4636-4646.
- Shao C, Liao CP, Hu P, Chu CY, Zhang L, Bui MH, Ng CS, Josephson DY, Knudsen B, Tighiouart M, Kim HL, Zhau HE, Chung LW, Wang R, Posadas EM. Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer. PLoS One. 2014;9(2):e88967.
- Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, Posadas EM. NanoVelcro chip for CTC enumeration in prostate cancer patients. Methods. 2013;64(2):144-152.